Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 1
2007 1
2008 2
2009 5
2010 1
2011 1
2012 6
2013 6
2014 4
2015 4
2016 13
2017 14
2018 11
2019 13
2020 17
2021 37
2022 27
2023 31
2024 36
2025 48

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Results by year

Filters applied: . Clear all
Page 1
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydén L, Marx N, Brosius FC 3rd, Mustafa RA, Agarwal A, Zou X, Mao Y, Asadollahifar A, Chowdhury SR, Zhai C, Gupta S, Gao Y, Lima JP, Numata K, Qiao Z, Fan Q, Yang Q, Jin Y, Ge L, Yang Q, Zhu H, Yang F, Chen Z, Lu X, He S, Chen X, Lyu X, An X, Chen Y, Hao Q, Standl E, Siemieniuk R, Agoritsas T, Tian H, Li S. Shi Q, et al. BMJ. 2023 Apr 6;381:e074068. doi: 10.1136/bmj-2022-074068. BMJ. 2023. PMID: 37024129 Free PMC article.
Reported harms were largely specific to drug class (eg, genital infections with SGLT-2 inhibitors, severe gastrointestinal adverse events with tirzepatide and GLP-1 receptor agonists, hyperkalaemia leading to admission to hospital with finerenone). Tirzepatide probably res …
Reported harms were largely specific to drug class (eg, genital infections with SGLT-2 inhibitors, severe gastrointestinal adverse events wi …
Pharmacological interventions for the acute treatment of hyperkalaemia: A systematic review and meta-analysis.
Jessen MK, Andersen LW, Djakow J, Chong NK, Stankovic N, Staehr C, Vammen L, Petersen AH, Johannsen CM, Eggertsen MA, Mortensen SØ, Høybye M, Nørholt C, Holmberg MJ, Granfeldt A; International Liaison Committee on Resuscitation (ILCOR) Advanced Paediatric Life Support Task Forces. Jessen MK, et al. Resuscitation. 2025 Mar;208:110489. doi: 10.1016/j.resuscitation.2025.110489. Epub 2025 Jan 4. Resuscitation. 2025. PMID: 39761907 Free article.
BACKGROUND: Hyperkalaemia is a life-threatening electrolyte disturbance and also a potential cause of cardiac arrest. ...No evidence supporting a clinical effect of calcium or bicarbonate for hyperkalaemia was identified....
BACKGROUND: Hyperkalaemia is a life-threatening electrolyte disturbance and also a potential cause of cardiac arrest. ...No evidence …
Association between antihypertensive treatment and adverse events: systematic review and meta-analysis.
Albasri A, Hattle M, Koshiaris C, Dunnigan A, Paxton B, Fox SE, Smith M, Archer L, Levis B, Payne RA, Riley RD, Roberts N, Snell KIE, Lay-Flurrie S, Usher-Smith J, Stevens R, Hobbs FDR, McManus RJ, Sheppard JP; STRATIFY investigators. Albasri A, et al. BMJ. 2021 Feb 10;372:n189. doi: 10.1136/bmj.n189. BMJ. 2021. PMID: 33568342 Free PMC article.
Secondary outcomes were acute kidney injury, fractures, gout, hyperkalaemia, hypokalaemia, hypotension, and syncope. Additional outcomes related to death and major cardiovascular events were extracted. ...The heterogeneity between studies assessing acute kidney injury and …
Secondary outcomes were acute kidney injury, fractures, gout, hyperkalaemia, hypokalaemia, hypotension, and syncope. Additional outco …
Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: A systematic review and meta-analysis.
Nguyen DV, Le TN, Truong BQ, Nguyen HTT. Nguyen DV, et al. Eur J Heart Fail. 2025 Jan;27(1):72-84. doi: 10.1002/ejhf.3454. Epub 2024 Sep 9. Eur J Heart Fail. 2025. PMID: 39252524 Free PMC article.

ARNI treatment showed benefits in the improvement of left ventricular end-systolic diameter, left ventricular mass index, left atrial diameter, and E/e' ratio (p < 0.05), while it did not significantly increase the risk of severe hyperkalaemia (p = 0.33) or symptomatic

…
ARNI treatment showed benefits in the improvement of left ventricular end-systolic diameter, left ventricular mass index, left atrial diamet …
Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis.
Shrestha DB, Budhathoki P, Sedhai YR, Baniya R, Cable CA, Kashiouris MG, Dixon DL, Kidd JM, Adhikari Y, Marasini A, Bhandari S. Shrestha DB, et al. Curr Ther Res Clin Exp. 2021 Jul 5;95:100635. doi: 10.1016/j.curtheres.2021.100635. eCollection 2021. Curr Ther Res Clin Exp. 2021. PMID: 34367383 Free PMC article. Review.
BACKGROUND: Patiromer and sodium zirconium cyclosilicate (SZC) are newer options for hyperkalemia treatment. This systematic review and meta-analysis were conducted to assess the safety and side effect profile of patiromer and SZC compared with placebo or other standards o …
BACKGROUND: Patiromer and sodium zirconium cyclosilicate (SZC) are newer options for hyperkalemia treatment. This systematic review a …
Treatment of diabetic kidney disease. A network meta-analysis.
Büttner F, Barbosa CV, Lang H, Tian Z, Melk A, Schmidt BMW. Büttner F, et al. PLoS One. 2023 Nov 2;18(11):e0293183. doi: 10.1371/journal.pone.0293183. eCollection 2023. PLoS One. 2023. PMID: 37917640 Free PMC article.
As primary endpoints, we defined: overall mortality and end-stage kidney disease, as secondary endpoints: renal composite outcome and albuminuria and as safety endpoints: acute kidney injury, hyperkalemia and hypotension. Under the use of a random effects model, we compute …
As primary endpoints, we defined: overall mortality and end-stage kidney disease, as secondary endpoints: renal composite outcome and albumi …
Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis.
Butler J, Usman MS, Khan MS, Greene SJ, Friede T, Vaduganathan M, Filippatos G, Coats AJS, Anker SD. Butler J, et al. ESC Heart Fail. 2020 Dec;7(6):3298-3309. doi: 10.1002/ehf2.13169. ESC Heart Fail. 2020. PMID: 33586910 Free PMC article.
A trend towards benefit was observed in patients with HF with preserved ejection fraction for the composite of HF hospitalization and cardiovascular death [HR: 0.80 (0.63-1.00); P = 0.05; I(2) = 29%]. No increased risk of hypovolaemia, hyperkalaemia, and hypotension was se …
A trend towards benefit was observed in patients with HF with preserved ejection fraction for the composite of HF hospitalization and cardio …
Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease : A Systematic Review and Retrospective Individual Participant-Level Meta-analysis of Clinical Trials.
Ku E, Inker LA, Tighiouart H, McCulloch CE, Adingwupu OM, Greene T, Estacio RO, Woodward M, de Zeeuw D, Lewis JB, Hannedouche T, Jafar TH, Imai E, Remuzzi G, Heerspink HJL, Hou FF, Toto RD, Li PK, Sarnak MJ. Ku E, et al. Ann Intern Med. 2024 Jul;177(7):953-963. doi: 10.7326/M23-3236. Epub 2024 Jul 2. Ann Intern Med. 2024. PMID: 38950402 Free PMC article.
LIMITATION: Individual participant-level data for hyperkalemia or acute kidney injury were not available. CONCLUSION: Initiation of ACEi or ARB therapy protects against KFRT, but not death, in people with advanced CKD. ...
LIMITATION: Individual participant-level data for hyperkalemia or acute kidney injury were not available. CONCLUSION: Initiation of A …
Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia.
Dong L, Xu W, Deng Y, Tan J, Qin W. Dong L, et al. Eur J Pharmacol. 2022 Sep 15;931:175174. doi: 10.1016/j.ejphar.2022.175174. Epub 2022 Aug 12. Eur J Pharmacol. 2022. PMID: 35964658
BACKGROUND: Gastrointestinal cation exchangers that can bind potassium in the gut, including sodium polystyrene sulfonate (SPS), calcium polystyrene sulfonate (CPS), patiromer and sodium zirconium cyclosilicate (SZC), are emerging medications for the treatment of hyperkalemia …
BACKGROUND: Gastrointestinal cation exchangers that can bind potassium in the gut, including sodium polystyrene sulfonate (SPS), calcium pol …
Ferroptosis in acute kidney injury following crush syndrome: A novel target for treatment.
Qiao O, Wang X, Wang Y, Li N, Gong Y. Qiao O, et al. J Adv Res. 2023 Dec;54:211-222. doi: 10.1016/j.jare.2023.01.016. Epub 2023 Jan 24. J Adv Res. 2023. PMID: 36702249 Free PMC article.
It is characterized by systemic inflammatory reaction, myoglobinuria, hyperkalemia and acute kidney injury (AKI). Especially AKI, it is the leading cause of death from CS. ...
It is characterized by systemic inflammatory reaction, myoglobinuria, hyperkalemia and acute kidney injury (AKI). Especially AKI, it …
249 results